Analysis shows improved validation of arsenic species in urine, indicating effectiveness of enhanced HPLC-ICP-MS methods.
Background: High-performance liquid chromatography–inductively coupled plasma mass spectrometry (HPLC-ICP-MS) is a critical analytical technique for determining the different forms of arsenic present in human urine. A new method was developed to overcome the shortcomings, such as poor resolution between critical arsenic species, of previously validated methods. The goal was to achieve resolution between 6 arsenic species that can be present in urine, including 2 common nontoxic organic species (arsenobetaine [AsB] and arsenocholine [AsC]), 2 methylated species with intermediate toxicity (monomethylarsonic acid [MMA] and dimethylarsinic acid [DMA]), and toxic inorganic forms (arsenous acid [AsIII] and arsenic acid [AsV]). In addition, efforts have been focused on identifying 2 unknown arsenic peaks present in approximately 5% of the patient population. Methods: HPLC-ICP-MS was developed using an anion-exchange analytical column with upfront dilution of urine samples. Some samples were reinjected into a high-performance liquid chromatography quadrupole time-of-flight tandem mass spectrometer (QTOF-MS) to identify the unknown compounds. Results: The newly developed method achieved adequate resolution for 6 known arsenic species. The method was successfully validated after additional challenges, such as stabilizing the transformation of certain arsenic species (AsB and AsIII), were resolved. A retrospective analysis of 3050 urine samples revealed positivity rates of 79.1% and 54.7% for AsB and DMA, respectively. All the other species were detected ≤2% of the time. Two unknown arsenic species analyzed by HPLC-QTOF-MS were identified as dimethylarsinoyl acetic acid (DMAA), a possible arsenosugar metabolite, and p-arsanilic acid (ASA), a likely contaminant from preanalytical exposure to urinalysis test strips. Conclusions: This new method improves the reliability of arsenic speciation analysis in urine, benefiting both clinical laboratories and patients.
No takes yet. Share an insight, caveat, or question.
Genesi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: